Clinical Trial Update: Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for nivolumab plus ipilimumab in aggressive pituitary tumors; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pituitary Cancer
• Pituitary Carcinoma
• Pituitary Tumor

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Pituitary, Pituitary Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING